RT Journal Article
T1 Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?
A1 Tejera Segura, Beatriz
A1 Altabás González, Irene
A1 Rúa-Figueroa, Iñigo
A1 Pérez Veiga, Natalia
A1 Del Campo Pérez, Victor
A1 Olivé-Marqués, Alejandro
A1 Galindo, María
A1 Calvo, Jaime
A1 Ovalles-Bonilla, Juan Gabriel
A1 Fernández-Nebro, Antonio
A1 Menor-Almagro, Raúl
A1 Tomero, Eva
A1 Del Val Del Amo, Natividad
A1 Uriarte Isacelaya, Esther
A1 Martínez-Taboada, Víctor Manuel
A1 Andreu, Jose L
A1 Boteanu, Alina
A1 Narváez, Javier
A1 Movasat, Atusa
A1 Montilla, Carlos
A1 Senabre Gallego, Jose Miguel
A1 Hernández-Cruz, Blanca
A1 Andrés, Mariano
A1 Salgado, Eva
A1 Freire, Mercedes
A1 Machín García, Sergio
A1 Moriano, Clara
A1 Expósito, Lorena
A1 Pérez Velásquez, Clara
A1 Velloso-Feijoo, M L
A1 Cacheda, Ana Paula
A1 Lozano-Rivas, Nuria
A1 Bonilla, Gema
A1 Arévalo, Marta
A1 Jiménez, Inmaculada
A1 Quevedo-Vila, Víctor
A1 Manero-Ruiz, Francisco J
A1 García de la Peña Lefebvre, Paloma
A1 Vázquez-Rodríguez, Tomás Ramón
A1 Ibañez-Rua, Jesús
A1 Cobo-Ibañez, Tatiana
A1 Pego-Reigosa, Jose María
K1 damage
K1 gastrointestinal disease
K1 systemic lupus erythematosus
AB SLE can affect any part of the gastrointestinal (GI) tract. GI symptoms are reported to occur in >50% of SLE patients. To describe the GI manifestations of SLE in the RELESSER (Registry of SLE Patients of the Spanish Society of Rheumatology) cohort and to determine whether these are associated with a more severe disease, damage accrual and a worse prognosis. We conducted a nationwide, retrospective, multicentre, cross-sectional cohort study of 3658 SLE patients who fulfil ≥4 ACR-97 criteria. Data on demographics, disease characteristics, activity (SLEDAI-2K or BILAG), damage (SLICC/ACR/DI) and therapies were collected. Demographic and clinical characteristics were compared between lupus patients with and without GI damage to establish whether GI damage is associated with a more severe disease. From 3654 lupus patients, 3.7% developed GI damage. Patients in this group (group 1) were older, they had longer disease duration, and were more likely to have vasculitis, renal disease and serositis than patients without GI damage (group 2). Hospitalizations and mortality were significantly higher in group 1. Patients in group 1 had higher modified SDI (SLICC Damage Index). The presence of oral ulcers reduced the risk of developing damage in 33% of patients. Having GI damage is associated with a worse prognosis. Patients on a high dose of glucocorticoids are at higher risk of developing GI damage which reinforces the strategy of minimizing glucocorticoids. Oral ulcers appear to decrease the risk of GI damage.
YR 2021
FD 2021
LK https://hdl.handle.net/10668/25102
UL https://hdl.handle.net/10668/25102
LA en
DS RISalud
RD Apr 7, 2025